CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
Clofarabine and Cytarabinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00334074
NCT00334074Phase 2Completed
CompareCT.gov

Phase II Trial of Clofarabine and Cytarabine in Relapsed Standard-Risk AML and Untreated High-Risk MDS in Adult Patients, and Untreated AML in Selected Elderly Patients at High Risk of Anthracycline Toxicity

Baylor Research Institute·interventional·Posted Jun 6, 2006·Updated Jul 17, 2013

In Brief

A Phase 2 clinical trial evaluating Clofarabine and Cytarabine for Acute Myelogenous Leukemia and 2 related conditions. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The purpose of this trial is to to determine the safety and effectiveness of therapeutic combination - Clofarabine and Cytarabine for the treatment of AML and MDS.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myelogenous Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 6, 2006
Enrollment StartAug 1, 2005
Primary CompletionFeb 1, 2007
Study CompletionFeb 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 20.1 years ago

Interventions

Clofarabine and Cytarabinedrug

Phase II Trial of Clofarabine and Cytarabine in Relapsed Standard-Risk AML and Untreated High-Risk MDS in Adult Patients, and Untreated AML in selected Elderly Patients at high risk of anthracycline toxicity